The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or ...

GSK Plc’s blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of ...

The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...

GSK has failed to win the backing of influential advisers to the US drugs regulator for a key blood cancer drug, putting its ...

London’s FTSE 100 was up 0.2% at 8,986.82 in afternoon trade on Friday. BP was in the black as the oil giant agreed to sell ...

Find insight on GSK, Novartis , Sarepta Therapeutics and more in the latest Market Talks covering Health Care.

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...